Greenwich LifeSciences received European Medicines Agency approval to combine HLA-A*02 and non-HLA-A*02 breast cancer patients in its Phase III FLAMINGO-01 trial evaluating the immunotherapy GLSI-100. This change aligns European and US sites under one protocol, potentially doubling enrollment speed and expanding the market for the treatment. Preliminary data show a 70-80% reduction in breast cancer recurrence in non-HLA-A*02 patients, consistent with earlier Phase IIb results. The company plans further updates as it advances toward regulatory approval for both patient groups.
Citizens Community Bancorp, Inc. reported a Q2 earnings per share (EPS) of $0.11, significantly missing analyst expectations of $0.41, marking a 73.17% earnings surprise. The company's revenue also fell short at $16.11 million, slightly down from las...
Rambus Inc. is poised for growth in the AI memory market as it prepares to release its quarterly earnings report. Analysts expect an EPS of $0.72 and revenue around $199.3 million, up from $180.19 million last quarter, driven by increased demand for ...
Alliance Resource Partners reported Q2 revenue of $551.6 million, slightly below estimates, due to lower coal prices despite higher sales volumes. The company saw a 33.9% rise in net income to $79.6 million, supported by strong oil and gas royalties....
Welltower is set to report strong Q2 revenue growth of about $3.43 billion, a 34.5% increase year-over-year, reflecting robust demand in healthcare real estate. Earnings per share estimates vary widely, from $0.64 to $1.55, indicating uncertainty in ...
Christian Dior reported strong first-half 2026 results with €38.6 billion in sales and an operating profit of €8.7 billion, maintaining a high operating margin of 22.5%. The group saw a 3% organic sales growth in Q2, driven by strong performances in ...
